Seeking Alpha
Profile| ()  

Pfizer reports a jump in Q4 net income to $9.45b, or $1.32/share, versus $2.73b, or $0.37/share, helped by the $7.9 billion profit from the sale of its consumer division to Johnson & Johnson. Adjusted earnings of $0.43/share beat analysts' average estimate of $0.42/share, but is a 12% decline from $0.49/share last Q4. Revenue totaled $12.6b, a 0.4% increase y-o-y, also beating analysts' estimate of $12.26b. Pfizer-PFE-1yr-chart-01-19-07 Sales of prescription drugs, which account for more than 90% of Pfizer's revenues increased by approx. $20m to $11.67b, hurt most noticeably by a 79% drop in worldwide sales of Zoloft to $166m. In its analyst meeting this afternoon in New York, Pfizer will discuss its guidance for 2007 and CEO Jeffrey Kindler is expected to elaborate on additional cost-cutting plans. In pre-market trading Pfizer's shares were up about 0.8% at $27.45, from Friday's close of $27.22 on volume slightly over 100k.

• Sources: Earnings press release, Bloomberg, WSJ
• Related commentary: Pfizer CEO Kindler Set To Overhaul Budget, Antidepressant Drug Market: New FDA Warning To Have Limited Impact, Pfizer Trading Well Below Its Intrinsic Value, Howling At The Moon: Dogs and Flying Five 2007 Stock Picks
• Potentially impacted stocks and ETFs: Pfizer (PFE). ETFs: iShares Dow Jones US Pharmaceuticals (IHE), iShares Dow Jones US Healthcare (IYH), Pharmaceutical HOLDRs (PPH), Vanguard Health Care (VHT), Health Care Select SPDR (XLV), First Trust Morningstar Dividend Leaders (FDL)

Seeking Alpha's news summaries are combined into a pre-market briefing called Wall Street Breakfast. Get Wall Street Breakfast by email -- it's free and takes only a few seconds to sign up.

Source: Pfizer Beats Street Estimates; All Eyes on CEO Kindler's Cost Cutting Plans